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Abstract
Purpose Two to seven percent of the German adult population has a renal impairment (RI) with an estimated glomerular filtration
rate (eGFR) < 60ml/min/1.73m2. This often remains unrecognized and adjustment of drug therapy is lacking. To determine renal
function in clinical routine, the CKD-EPI equation is used to calculate an indexed eGFR (ml/min/1.73m2). For drug dosing, it has
to be individualized to a non-indexed eGFR (ml/min) by the patient’s body surface area. Here, we investigated the number of
patients admitted to urological wards of a teaching hospital with RI between July and December 2016. Additionally, we correctly
used the eGFRnon-indexed for drug and dosage adjustments and to analyse the use of renal risk drugs (RRD) and renal drug-related
problems (rDRP).
Methods In a retrospective observational study, urological patients with pharmacist-led medication reconciliation at hospital
admission and eGFRindexed (CKD-EPI) of 15–59 ml/min/1.73m
2 were identified. Indexed eGFR (ml/min/1.73m2) was
recalculated with body surface area to non-indexed eGFR (ml/min) for correct drug dosing. Medication at admission was
reviewed for RRD and based on the eGFRnon-indexed for rDRP, e.g. inappropriate dose or contraindication.
Results Of 1320 screened patients, 270 (20.5%) presented with an eGFRindexed of 15–59ml/min/1.73m
2. After readjustment, 203
(15.4%) patients had an eGFRnon-indexed of 15–59 ml/min. Of these, 190 (93.6%) used ≥ 1 drugs at admission with 660 of 1209
(54.7%) drugs classified as RRD. At least one rDRP was identified in 115 (60.5%) patients concerning 264 (21.8%) drugs.
Conclusion Renal impairment is a common risk factor for medication safety in urologic patients admitted to a hospital. Considerable
shifts were seen in eGFR-categories when correctly calculating eGFRnon-indexed for drug dosing purposes. The fact that more than half
of the study patients showed rDRP at hospital admission underlines the need to consider this risk factor appropriately.
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Introduction
Renal impairment (RI), defined as an estimated glomerular
filtration rate (eGFR) < 60 ml/min/1.73m2 [1], is a relevant
health issue in Germany. About 2–7% of the adult population
are affected rising to 15–25% in patients aged over 60 years
[1–3]. Unfortunately, in 72% of these patients, the RI remains
unrecognized and only two-thirds of those, who are aware, are
in medical care [2]. Adjustment of drug therapy is an impor-
tant issue of patient safety in this patient group to avoid ad-
verse drug reactions (ADR).
‘Renal risk drugs’ (RRD) either show altered pharmacoki-
netics or pharmacodynamics in RI or directly affect renal
function [3, 4]. Dosage reduction and discontinuation of the
drug or possibly harmful drug combinations have to be con-
sidered to avoid accumulation or nephrotoxicity, potentially
leading to ADR [5, 6]. Additionally, drug activation (e.g. vi-
tamin D) or pharmacological effectiveness (e.g. thiazides)
may be influenced by RI [7, 8]. Inappropriate or missing ad-
justment of RRD to renal function may cause renal drug-
related problems (rDRP). Many rDRP are preventable if renal
function is consequently considered. However, poor aware-
ness of pre-existing RI and incorrect use of equations for renal
function is still a problem. The use of potentially inappropriate
drugs and dosages is common in patients with RI [9–12],
increasing the rate of ADR [13–16].
In routine clinical practice, renal function is mostly deter-
mined using the endogenous filtration marker creatinine to
calculate an eGFR or an estimated creatinine clearance (Fig.
S1) [9].
To stage chronic kidney disease (CKD) for diagnosis, prog-
nosis and treatment, the Kidney Disease Improving Global
Outcomes Initiative (KDIGO) recommends the calculation of
eGFR using the CKD Epidemiology Collaboration (CKD-EPI)
equation and graduates eGFR in six categories [1, 17, 18].
CKD-EPI-equation estimates GFRindexed for a standard body
surface area (BSA) of 1.73 m2 and can be used to compare
renal function regardless of the individual’s size and weight.
Importantly, for drug dosing, the GFRindexed should be individ-
ualized for every patient to the units ml/min by adjusting for the
BSA calculated from actual weight and height (eGFRnon-
indexed) [1, 18, 19]. This is of special importance for patients
whose BSA differs significantly from 1.73 m2 and for drugs
with a narrow therapeutic index, yet since eGFRindexed is cal-
culated automatically by many clinical laboratories, physicians
tend to incorrectly use this parameter for drug dosing.
In comparison, the Cockcroft-Gault (CG) equation con-
siders patients’ weight and estimates a creatinine clearance
in ml/min [20]. It can directly be used for drug dosing and
has been the standard for dose recommendations in most sum-
mary of product characteristics (SPC) in the last decades, but it
has to be discussed which weight (e.g. total, ideal, adjusted or
lean body weight) to use [21–24].
In addition to CKD, acute kidney injury (AKI) has to be
considered when drugs are prescribed. This is especially im-
portant in urologic patients, who often present with urinary
flow obstructions at hospital admission. This may be transito-
ry, but still overdosage and inappropriate drug selection are of
immediate concern. Estimating renal function in AKI is chal-
lenging since creatinine is not in a steady-state [1].
With hospital admission, the physician on ward becomes
responsible for a patient’s drug therapy. The ambulant medi-
cations are generally continued during hospital stay.
Therefore, dosing errors that have been introduced in ambu-
lant care may be continued during the hospital stay and cause
ADR, if not identified and corrected at the time of hospital
admission. In our hospital, a pharmacist-led medication rec-
onciliation is supporting this process. Since RI often remains
unrecognized in outpatients, screening for decreased eGFR
and rDRP at this transition of care is important.
To our knowledge, no data exist about the prevalence of
impaired renal function in patients admitted to an urologic
department of a tertiary teaching hospital. It is currently un-
known, if and which RRD are taken by these patients and if
rDRP exist. Additionally, the impact of using the eGFRnon-
indexed (actual BSA) rather than the eGFRindexed (standard-
BSA) in clinical routine has not been addressed yet.
The objective of this study was to determine the number of
patients admitted to urological wards presenting with RI and
to evaluate how many of these patients changed eGFR-
categories when referring to indexed vs. non-indexed eGFR,
estimated with the CKD-EPI-equation. In addition, patients
with eGFRnon-indexed 15–59 ml/min were further analysed re-
garding RRD and rDRP concerning pre-existing drug therapy.
Methods
Patients, setting and design
We conducted a retrospective observational study of patients
at the time of hospital admission to two urological wards of
the University HospitalMunich, Germany, between July 2016
and December 2016. Patients were included if they were ≥
18 years of age and received a pharmacist-led medication
reconciliation at admission, generating a structured medica-
tion plan of all prescribed and over the counter drugs used.
Readmissions were included, since the study was designed to
represent a real-life setting and patient’s renal function may
change over time.
The following data were collected: age, gender, height,
weight, eGFRindexed, drugs at admission including drugs on-
demand and scheduled medications and comorbidities known
to affect renal function. Body mass index (BMI), BSA
(Mosteller equation) and eGFRnon-indexed were calculated
[18, 25, 26].
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Ethical approval
The study was conducted in accordance with the Declaration
of Helsinki. Ethical approval was obtained from the ethics
committee at Ludwig-Maximilians-University Munich, regis-
tration number 778-16.
Data collection
Data were collected from the hospital’s electronical patient
information system (SAP-i.s.h.med, Cerner Corporation,
North Kansas City, USA) that includes medical reports, diag-
noses and administrative documents. Drugs and dosages were
extracted from themedication plans generated by a pharmacist
at admission. Comorbidities were recorded either from SAP-
i.s.h.med or derived from the indication of drugs taken, e.g.
statins for hypercholesterolemia.
Renal impairment
The eGFRindexed was automatically calculated by the clinical
laboratory using the CKD-EPI-equation with standardized se-
rum creatinine [27–29]. The pharmacist estimated BSA and
readjusted the eGFRindexed to eGFRnon-indexed for drug dosing
recommendations by using the equation eGFRnon-indexed =
eGFRindexed/1.73 m
2 × BSA [18].
Identification of ‘renal risk drugs’ and renal drug-
related problems
Furthermore, patients with eGFRnon-indexed 15–59 ml/min
were identified and their medication at admission was
screened for renal risk drugs (RRD) and renal drug-related
problems (rDRP). RRD/rDRP were analysed for subgroups
of eGFR-categories (15–29, 30–44 and 45–59 ml/min). The
medications of patients with eGFRnon-indexed > 60 ml/min usu-
ally do not need dose or drug adaption and patients with
eGFRnon-indexed < 15 ml/min are routinely under the care of a
nephrologist; thus, they were not further analysed in this
study.
The evaluation whether a drug was a RRD and whether the
dosage was incorrect or contraindicated with the individual’s
eGFRnon-indexed was based on the information given in the
German SPC or the drug information database AiDKlinik®
that refers to the renal dose recommendation portal Dosing®
(www.dosing.de). In case of discrepancies, an additional
source was consulted [30].
Classification of renal drug-related problems
The renal drug-related problems (rDRP) were classified in
consensus decision by three clinical pharmacists. rDRP were
categorized with regard to ‘PCNE Classification’ and
previous studies concerning rDRP (Fig. 1) [3, 4, 31]. All
rDRP were classified as potential or manifest depending on
the individual’s eGFRnon-indexed. Manifest rDRP are present
with the current eGFRnon-indexed. Potential rDRP concern
eGFRnon-indexed-values at threshold range (until +15 ml/min)
and action must be taken when renal function decreases fur-
ther. The actual incidence of adverse clinical events resulting
from rDRP was not investigated.
Fig. 1 Classification of potential/manifest renal drug-related problems
depending on an individual’s eGFR (ml/min). The renal drug-related
problem (rDRP) of either treatment safety or treatment effectiveness is
categorized in one main cause and more than one intervention might be
necessary to solve rDRP. CK, creatine kinase; ADR, adverse drug
reaction
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The rDRP concern either treatment safety or treatment ef-
fectiveness and are categorized in onemain cause inducing the
rDRP. One rDRP may lead to one or more interventions.
The suggested interventions were related to drug level and/
or need for ‘monitoring’. Monitoring refers to control of se-
rum blood levels (e.g. electrolytes, creatine kinase) or ADR.
Monitoring of serum creatinine and eGFR was not included
since it is mandatory in this patient population.
Statistical analysis
Data at admission were analysed using descriptive statis-
tics. Qualitative variables are presented with their frequen-
cy distribution. Quantitative variables are expressed as the
median and interquartile range (data without normal distri-
bution). For comparison of the patient’s characteristics
concerning age and gender, Chi-square test was used for
categorical variables (independent samples) and Mann-
Whitney U test for continuous variables (without normal
distribution, independent samples). Statistical significance
was accepted as p < 0.05.
Statistical analyses and figures were performed with
Microsoft Excel® 2016 (Seattle, WA, USA) and IBM SPSS
Statistics® version 25.0 (Armonk, NY, USA).
Results
Identification and categories of renal impairment: the
impact of eGFRindexed versus eGFRnon-indexed
During the 6-month study period, 1341 patients were admit-
ted. For 1320 (98%) patients, pharmacist-led medication rec-
onciliation was performed. The majority of all patients were
male (82.6%) and the median age 67 (18–94) years. Baseline
characteristics of all patients are shown in Table 1.
As there is an uncertainty regarding which formula is rou-
tinely used for drug dosing purposes in clinical routine, we
investigated the impact on the number of patients with renal
impairment (RI) using eGFRindexed versus eGFRnon-indexed.
Two hundred seventy (20.5%) patients had an eGFRindexed
of 15–59 ml/min/1.73m2 and 16 (1.2%) patients presented
with eGFRindexed < 15 ml/min/1.73m
2. However, the median
BSA for all patients was noticeably higher than 1.73 m2 (me-
dian 1.97 m2, 1.17–2.86). When taking the patients’ actual
BSA into account and recalculating to eGFRnon-indexed, 67
(5.1%) patients were no longer in the critical range of 15–
59 ml/min (Figs. 2 and 3).
The remaining 203 (15.4%) patients in the critical
eGFRnon-indexed-range of 15–59 ml/min were older (median
age 76 (30–94) years) in comparison with patients with
eGFR ≥ 60 ml/min and significantly more often presented
with comorbidities such as arterial hypertension,
cardiovascular disease or hyercholesterolemia. There was no
significant difference in the occurrence of prostatic
hyperthrophy (p = 0.98), diabetes mellitus type 2 (p = 0.32)
and urinary flow obstructions (p = 0.08).
Comparing male and female patients with eGFRnon-indexed
15–59 ml/min, male patients presented with higher BMI and
BSA, but no significant difference in age (p = 0.31), number
of drugs (p = 0.62), and eGFRnon-indexed (p = 0.69) was found.
The comorbidities differed regarding hyperuricemia and car-
diovascular diseases.
Comparing patients aged < 65 and ≥ 65 years, eGFRnon-
indexed did not significantly differ (p = 0.88), while older pa-
tients took more drugs (p < 0.05).
RRD and rDRP in patients with eGFRnon-indexed 15–
59 ml/min
As the eGFRnon-indexed should correctly be used for dosing
drugs, we next deciphered the occurrence of RRD and
rDRP in the patients with eGFRnon-indexed of 15–59 ml/
min. One hundred ninety (93.6%) of the 203 patients took
one or more drugs at admission (Table 2). In total, 1209
drugs were documented for these patients with a median
number of 6 (1–18) drugs per patient. Out of these, 660
(54.7%) were identified as RRD with a median of 3 (0–
11) RRD per patient. The 1209 drugs taken represented
218 different substances according to the Anatomical
Therapeutic Chemical (ATC) classification system with
113 (51.8%) matching the criteria of RRD.
Of the 660 RRD, 264 RRD led to rDRP concerning 76
different substances. This represents 21.8% of all medica-
tions and 40.0% of the RRD. One hundred fifteen patients
of 190 (60.5%) had rDRP already at hospital admission.
The 260 documented rDRP represented a median number
of 2 (0–10) rDRP per patient (Table 2). In two cases, the
rDRP was a ‘drug combination potentially decreasing renal
function’ triggered by three drugs. Thus, the number of
RRD (n = 264) is higher than the number of rDRP (n =
260).
Detailed analysis of rDRP
For all patients with rDRP (eGFRnon-indexed 15–59 ml/min;
n = 115), more manifest (58.5%) than potential (41.5%)
rDRP were found (Fig. 4). Enoxaparin and colecalciferol,
followed by ramipril, spironolactone, hydrochlorothiazide,
simvastatin and metformin are the drugs most often associated
with rDRP (Fig. S2). The most frequent intervention for man-
ifest rDRP would have been ‘monitoring’ and ‘dosage
change’, and for potential rDRP ‘dosage change’ and ‘drug
change/drug stop’.
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Discussion
In this study, for the first time, the prevalence and the nature of
RRD and rDRP were assessed in patients presenting with RI
at admission to urological wards in a tertiary teaching hospital.
Of note, we found that over half of the drugs taken at admis-
sion are RRDwith 40.0% of these leading to rDRP. The use of
indexed versus non-indexed eGFR has a noticeable impact on
the determination of renal function, in turn influencing drug
dosing and thus patient safety.
Table 1 Baseline characteristics
of all patients with pharmacist-led
medication reconciliation, and for
the eGFRnon-indexed-category sub-
groups. Data are quoted as the
median (interquartile range) or n
(%)
eGFR categories (ml/min) Overall < 15 15–59 ≥ 60
No. of patients (n) 1320* 15 203 1102
Males 82.6% 66.7% 73.4% 84.5%
Age (years) 67 (18–94) 72 (33–93) 76 (30–94) 66 (18–94)
18–39 7.5% 46.7% 0.5% 8.8%
40–59 21.4% 20.0% 7.4% 24.0%
60–64 12.5% 0.0% 9.4% 13.2%
65–74 29.8% 26.7% 25.1% 30.8%
≥ 75 28.8% 46.7% 57.6% 23.2%
eGFRnon-indexed (ml/min) 94 (9–213) 11 (9–14) 45 (15–59) 100 (60–213)

















< 18,5 2.2% 14.3% 3.0% 1.8%
18.5–24.9 38.8% 57.1% 50.5% 36.4%
25–29.9 39.8% 14.3% 33.2% 41.4%









No. of drugs at admission (n) 3 (0–20) 8 (1–13) 5 (0–17) 3 (0–17)
0 17.7% 0.0% 6.4% 20.0%
1 or 2 23.9% 6.7% 17.2% 25.4%
3 or 4 18.5% 6.7% 22.2% 18.0%
5 or 6 14.8% 26.7% 12.8% 15.1%
7 or 8 11.7% 13.3% 13.8% 11.3%
9 or 10 7.0% 20.0% 14.8% 5.4%
> 10 6.4% 26.7% 12.8% 4.9%
Comorbidities n (%) n (%) n (%) n (%)
Arterial Hypertension 655 (49.6) 13 (86.7) 140 (69.0) 502 (45.6)
Diabetes mellitus type 2 192 (14.5) 3 (20.0) 34 (16.7) 155 (14.1)
Hypercholesterolemia 317 (24.0) 7 (46.7) 62 (30.5) 248 (22.5)
Cardiovascular disease 114 (8.6) 3 (20.0) 33 (16.3) 78 (7.1)
Heart failure 38 (2.9) 2 (13.3) 18 (8.9) 18 (1.6)
Pulmonary disease 94 (7.1) 1 (6.7) 21 (10.3) 72 (6.5)
Hyperuricemia 132 (10.0) 4 (26.7) 35 (17.2) 93 (8.4)
Prostatic hypertrophy 317(29.1**) 3 (30.0**) 49 (32.9**) 265 (28.5**)
Outflow problems or obstruction of
urinary tract
203 (15.4) 6 (40.0) 39 (19.2) 158 (14.3)
Hydronephrosis 250 (18.9) 8 (53.3) 87 (42.9) 155 (14.1)
Kidney transplant 6 (0.5) 1 (6.7) 2 (1.0) 3 (0.3)
*222 (16.8%) readmissions**referring to males
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Fig. 2 Patient flow of all patients
admitted to two urological wards
during 6 months
Fig. 3 Distribution of patients
with eGFRindexed and eGFRnon-
indexed according to
eGFR-categories (n = 1320)
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We found 21.7%of patients to haveRIwith an eGFRindexed <
60ml/min/1.73m2 at hospital admission. The number of affected
patients was expected to be higher in urology, since urinary flow
obstructions and prostatic hypertrophy are typical for patients
admitted to urologic wards, but this is within the similar range
reported by other studies for all hospitalized patients or patients
admitted to internal medicine [3, 6]. There was however no dif-
ference in the occurrence of prostatic hypertrophy or urinary flow
obstructions in the different eGFR-subgroups. We could not dis-
tinguish the percentage of patients with AKI or CKD or a com-
bination of both at hospital admission, since eGFR-values from
the past were rarely available.
Screening for RI at hospital admission is especially important
considering that up to 72% of non-hospitalized CKD patients are
not aware of their kidney insufficiency [2] and RI is an
established risk factor for DRP [32]. Regarding the adjustment
of drug therapy to renal function, it is vital to understand which
estimation of GFR or renal clearance to use. For the classification
of severity of the disease, international guidelines mainly recom-
mend the use of the CKD-EPI-equation standardized to BSA of
1.73 m2 [1]. For drug dosing purposes, a measurement for renal
function in ml/min (eGFRnon-indexed or eKreaCl) should be used
[19]. Noteworthy, most patients in this study had a higher BSA
(median 1.97 m2, range 1.17–2.86) than the standard BSA of
1.73 m2, which influences the calculation of eGFRnon-indexed.
Indeed, we detected a considerable shift of patients between
eGFR-subgroups when readjusting for actual BSA, resulting in
a distinct decrease in the number of patients to consider for drug
therapy adjustment. In fact, obesity is a rising problem in the last
years and has to be considered for the estimation of renal function
and drug dosing. Recent reviews summarize that for drug dosing,
eGFRindexed underestimates renal function, and therefore,
eGFRnon-indexed should be used [22, 23]. Indeed, our data suggest
that the patient’s individual weight and height have to be increas-
ingly considered, and subsequently, eGFRindexed must be adjust-
ed to patients’ actual BSA for correct drug dosing. This recalcu-
lation to eGFRnon-indexed for drug dosing was not considered in
comparable studies [3, 4]. Nevertheless, in our opinion, this is a
crucial point to be stressed, since many practitioners are not
aware of the differences between the calculations and their im-
pact on determining renal function and thus drug dosing.
This study focused on patients with an eGFRnon-indexed 15–
59ml/min for two reasons. Firstly, adjustment of drug therapy
is usually necessary for GFRnon-indexed < 60 ml/min [30].
Secondly, whereas patients with < 15 ml/min are normally
under supervision of a nephrologist, patients with 15–59 ml/
min are generally not and are therefore at increased risk for
rDRP. Although we adjusted the eGFRindexed to the actual
BSA (eGFRnon-indexed), the number of patients displaying
one or more rDRP (61%) and the median number of rDRP/
patient was similar to studies from other medical departments
using the eGFRindexed [3, 4]. However, in our study, every
Table 2 Renal risk drugs (RRD) and renal drug-related problems (rDRP) in patients with eGFRnon-indexed 15–59 ml/min and ≥ 1 drug (n = 190). Data
are quoted as the median (interquartile range) or n (%)
eGFR categories
eGFRnon-indexed (ml/min) Overall 15–59 15–29 30–44 45–59
No. of patients n 190 39 56 95
Drugs at admission n 1209 278 361 570
median (range) 6 (1–18) 6 (1–18) 6 (1–17) 5 (1–14)
Renal Risk Drugs (RRD) n (%) 660 (54.7) 160 (57.5) 187 (51.8) 313 (54.9)
No. of RRD per patient median (range) 3 (0–11) 4 (0–11) 3 (0–10) 3 (0–9)
RRD with rDRP n (%) 264* (21.8**) 107* (38.5**) 85* (23.5**) 72* (12.6**)
Patients with rDRP n (%) 115 (60.5) 31 (79.5) 35 (62.5) 49 (51.6)
No. of rDRP per patient median (range) 2 (0–10) 2 (0–10) 2 (0–7) 1 (0–4)
No. of rDRP n 260 105 85 70
Potentiala n (%) 108 (41.5) 14 (13.3) 61 (71.8) 33 (47.1)
with only monitoringb n (%) 10 (9.3#) 0 (0.0) 6 (10.0#) 4 (12.1#)
Manifestc n (%) 152 (58.5) 91 (86.7) 24 (28.2) 37 (52.9)
with only monitoringb n (%) 57 (37.2#) 26 (28.6#) 14 (56.0#) 17 (45.9#)
*Drugs were counted separately, when there was a drug interaction potentially decreasing renal function (two or three drugs per interaction)
**Percentage value refers to drugs at admission
#Percentage value refers to potential or manifest rDRP
a: eGFR must be monitored, if it decreases, action must be taken
b: Monitoring as only intervention: Serum blood value (e.g. electrolytes) or adverse drug reaction must be monitored
c: rDRP is currently present with the current eGFR
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second drug was classified as RRD with about 40.0% of the
RRD associated with rDRP, which is somewhat higher com-
pared with other studies [3]. One reason for this might be that
patients are admitted to an university hospital with more seri-
ous health problems, demanding consultation of specialists.
This could lead to a higher number of drugs taken by patients
at a university hospital compared with non-university hospi-
tals. However, we did not test this hypothesis. Manifest rDRP
accounted with 58.5% for the majority of detected rDRP in
our study. Use of suboptimal drugs, followed by overdosage
and the presence of contraindications, were the causes in most
cases.
Fig. 4 Potential and manifest renal drug-related problems (rDRP) (n =
260) in patients with eGFRnon-indexed of 15–59 ml/min and ≥ 1 drug (n =
190). a Type of rDRP. b Causes of rDRP. c Interventions that should be
proposed to prescriber to solve rDRP. Potential: eGFR must be moni-
tored, if it decreases, action must be taken. Manifest: rDRP is currently
present.
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When distinguishing further in eGFR-subgroups, which
represent common dosage frames, more manifest rDRP are
seen in lower eGFR-ranges. Of note, more than half of man-
ifest rDRP concerning treatment safety occurred in patients
with an eGFRnon-indexed 15–29 ml/min. The most frequently
prescribed RRD associated with manifest rDRP in our patient
population was low molecular weight heparins (LMWH;
enoxaparin in this case). The unadjusted dosage of LMWH
leads to a higher bleeding risk for patients with RI [30, 33].
Our data indicate that the awareness of correct prescribing of
LMWH in patients with RI still seems to be problematic in the
ambulant setting and therefore may also be a risk factor in the
hospital setting.
Renal function can alter quickly in urologic patients after
hospital admission, e.g. impairing in the perioperative period
or improving after correction of urinary flow obstructions
[34–36]. Therefore, we think it is important not only to focus
on manifest rDRP but also to point out potential rDRP that
may suddenly become relevant. The leading cause for poten-
tial rDRPwas overdosage, followed by contraindication or the
use of a suboptimal drug. This is in line with the findings of
other studies where non-optimal dose and non-optimal drugs
were the main causes for rDRP [3, 4]. The most frequently
prescribed drug associated with potential rDRP was vitamin
D. Indeed, there are still uncertainties regarding the use (indi-
cation and type of vitamin D derivative) of vitamin D and its
derivatives depending on renal function [7]. Physicians follow
recommendations to prescribe vitamin D to patients with RI.
As the main activation from colecalciferol to calcitriol takes
place in the kidneys, a change of prescription to the activated
form has to be considered from a certain stage of kidney dis-
ease on. In our experience, this is often neglected and there is a
need of further guidance how to prescribe vitamin D deriva-
tives depending on the severity of RI.
Additionally, it has to be kept in mind that some drugs are
specifically used against their labeling e.g. hydrochlorothia-
zide in combination with loop diuretics with an eGFR <
30 ml/min, and should not be classified as rDRP. Thus, it is
important to use renal dosing references additionally to the
SPC to determine RRD.
In non-hospitalized patients, inappropriate prescribing in
RI was found in up to 80% and associated with more ADR,
a longer hospital stay and a higher mortality risk [10, 12].
Thus, at hospital admission, screening for affected patients is
of great importance as a proactive risk management.
Physicians and pharmacists should work together to achieve
safer drug prescribing [13]. The most significant reduction of
inappropriate prescribing in patients with RI has indeed been
observed when physicians received immediate feedback from
pharmacists [12]. Prescription review followed by recommen-
dations by a pharmacist has been shown to positively influ-
ence clinical outcome and even reduce costs of hospital stay
[37]. In our study, for manifest and potential rDRP, the three
most often recommended interventions to the physician on
ward would have been monitoring, change of dosage and
change or discontinuation of a drug.
Furthermore, it is important to recalculate the automatically
reported eGFRindexed to the eGFRnon-indexed before assessing
the medication. In our experience, this recalculation is not
usually performed by physicians on wards and the support
of a pharmacist would be important. Moreover, the use of
medication plans derived from medication reconciliation by
a pharmacist at hospital admission, as in this study, can iden-
tify patients at risk. It has been shown that these plans are more
complete and accurate compared with medication plans pre-
pared by physicians [38, 39].
Some limitations of the study should be considered. This
retrospective study focused on rDRP but did not assess possi-
bly related adverse drug reactions, which should be included
in future evaluations. Readmissions were included in our
study to represent a real-life setting and because patient’s renal
function may change over time. However, this might have
over- or underestimated the prevalence of RI in our study
population. In addition, we assumed comorbidities from the
indication of drugs taken by the patients because experiences
from previous evaluations revealed that the documentation of
diagnoses is often poor. This allows a more complete charac-
terisation of the comorbidities in our study population.
However, at the same time, due to drugs given without indi-
cation or due to diseases not treated adequately with drugs,
errors may be included in our evaluation.
Conclusion
Our study provides novel evidence that urological patients with
RI take a high number of RRD at hospital admission, leading to
a substantial number of rDRP. This may be a risk factor for
patient safety during the hospital stay. In addition, our analyses
demonstrate considerable shifts of patients between eGFR-
categories when recalculating eGFR from standard-BSA
(indexed eGFR; ml/min/1.73m2) to individual BSA (non-
indexed eGFR; ml/min) for drug dosing purposes. This is an
important point to avoid over- and underdosing or mistakes in
contraindications that are frequently overlooked so far.
Future goals should be to develop a risk assessment to
simplify the identification of the concerned patients during
the pharmacist-led medication reconciliation at admission
and to investigate the best way to inform physicians on ward
about inappropriate drug use to ensure appropriate prescribing
during the hospital stay.
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